TICKERNERD
Menu
TARATARAHealthcare · Biotechnology

TARA Stock Forecast: Protara Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$2.52
+1.00% on the day

The 8 Wall Street analysts covering Protara Therapeutics, Inc. hold a median 12-month price target of $26 — +933.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 29 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$146.0M
Ticker Nerd rank
33/ 100
Median analyst target
$26
Analysts covering
8
Revenue$0.0
Operating income−$23.3M
Net income−$21.7M
Free cash flow−$15.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.1%
1M
−21.7%
YTD
−52.8%
1Y
−51.6%
From 52W high
−66.7%
From 52W low
+8.4%
$2.32
$7.56
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TARA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Protara Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 29 Oct 2026
33/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
70
Quality
67
Volatility
58
Accruals
54
Revisions
39
Issuance
39
Value
32
Growth
29
Momentum
22

Size (70): Smaller than most of the companies we track.

Momentum (22): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TARA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TARA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00$30.00$35.00Jan 26Apr 26Jul 26Oct 26TARAHigh $30Median $26Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $20Median $26High $30

The green dot is the last close — the median target sits +933.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 May 2026OppenheimerMaintainsOutperform$25 → $28
14 May 2026JP MorganMaintainsOverweight$27 → $26
29 Apr 2026HC Wainwright & Co.MaintainsBuy—
4 Mar 2026JP MorganInitiatesOverweight—
10 Feb 2026HC Wainwright & Co.ReiteratesBuy—
7 Jan 2026Piper SandlerInitiatesOverweight—
3 Dec 2025HC Wainwright & Co.ReiteratesBuy—
19 Nov 2025HC Wainwright & Co.ReiteratesBuy—
22 May 2025Jones TradingInitiatesBuy—
28 Apr 2025HC Wainwright & Co.ReiteratesBuy—
16 Apr 2025ScotiabankInitiatesSector Outperform—
14 Mar 2025Cantor FitzgeraldInitiatesOverweight—
11 Mar 2025LifeSci CapitalInitiatesOutperform—
6 Mar 2025HC Wainwright & Co.ReiteratesBuy—
6 Dec 2024GuggenheimReiteratesBuy—
6 Dec 2024HC Wainwright & Co.ReiteratesBuy—
14 Nov 2024HC Wainwright & Co.ReiteratesBuy—
12 Aug 2024OppenheimerMaintainsOutperform—
8 Aug 2024HC Wainwright & Co.ReiteratesBuy—
6 May 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

TARA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

TARA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, Protara Therapeutics, Inc. returned −51.6% against +13.1% for the S&P 500, dividends included.

TARA vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140Jan 26Apr 26Jul 26Oct 26TARAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TARA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
5
Fundamentals

Protara Therapeutics, Inc. (TARA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.8×

Cheaper than 86% of US stocks

Price / sales
—
Price / book
0.9×

Cheaper than 73% of US stocks

EV / EBITDA
−0.1×

Cheaper than 63% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−45.8%

Higher than 23% of US stocks

Return on assets
−28.8%

Higher than 14% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Protara Therapeutics, Inc. (TARA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Protara Therapeutics, Inc. has a market value of $146.0M and an enterprise value of $6.2M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$70.0M.

  • Diluted earnings per share, trailing twelve months: $−1.35.

  • Free cash flow in the twelve months to 30 June 2026: −$66.5M.

  • Shares outstanding: 59.1M.

  • Trailing P/E: −1.8×; forward P/E: −1.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Protara Therapeutics, Inc. employs 46 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

TARA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TARAProtara Therapeutics, Inc.$146.0M33
STROSutro Biopharma, Inc.$149.8M74
MGNXMacroGenics, Inc.$151.3M60
NGENNervGen Pharma Corp.$154.8M22
CUECue Biopharma, Inc.$155.8M30
CNTNCanton Strategic Holdings, Inc.$158.1M12
MENSJyong Biotech Ltd.$139.6M3

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Protara Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TARA news & analysis

Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support

GlobeNewsWire · 15 Oct 2026positive

Protara Therapeutics completed enrollment of 24 patients in the Phase 2b open-label dose confirmation phase of its THRIVE-3 trial evaluating IV Choline Chloride in patients with intestinal failure dependent on parenteral support. The company said it remains on track to report interim results from the Phase 2b cohort in the fourth quarter of 2026.

Why it matters — Enrollment completion marks progress in the trial, and TARA watchers may follow the anticipated interim results in 4Q 2026.

Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 8 Sept 2026neutral

Protara Therapeutics announced that its management will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 2:00 pm ET. The company is a clinical-stage developer of therapies for cancer and rare diseases.

Why it matters — The upcoming presentation gives investors and analysts an opportunity to hear directly from Protara's management about its clinical-stage pipeline at a prominent investment conference.

Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline

Seeking Alpha · 11 Aug 2026positive

A Seeking Alpha analysis rates Protara Therapeutics as Buy, citing a risk-adjusted fair value of $9.96 per share versus a current price near $4. The article highlights its pipeline, including TARA-002 for NMIBC and Lymphatic Malformations with orphan drug indications, and IV Choline Chloride for severe choline deficiency in parenteral nutrition patients, with pivotal data expected in 2026.

Why it matters — A TARA watcher would care because the piece frames the company's orphan drug pipeline as heavily undervalued relative to its current share price and outlines upcoming catalyst data.

FAQ

Frequently asked questions about TARA stock

What is the TARA stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Protara Therapeutics, Inc. have a median 12-month price target of $26, with estimates ranging from $20 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TARA stock a buy right now?

Of the 8 analysts covering Protara Therapeutics, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Protara Therapeutics, Inc. 33 out of 100 across roughly 4,600 US stocks as at 29 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TARA?

As at 29 Oct 2026, Protara Therapeutics, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (70 of 100).

Will TARA stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +933.8% from the last close, and Ticker Nerd's factor model ranks Protara Therapeutics, Inc. 33 out of 100 as at 29 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TARA stock forecast for 2030?

No analyst covering Protara Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TARA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $30 over the next 12 months.

How has TARA stock performed over the past year?

Protara Therapeutics, Inc. returned -51.6% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Protara Therapeutics, Inc. do?

Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases.

What is the latest news on TARA?

The most recent item we track (GlobeNewsWire, 15 Oct 2026): "Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support". Protara Therapeutics completed enrollment of 24 patients in the Phase 2b open-label dose confirmation phase of its THRIVE-3 trial evaluating IV Choline Chloride in patients with intestinal failure dependent on parenteral support. The company said it remains on track to report interim results from the Phase 2b cohort in the fourth quarter of 2026.

Company

About Protara Therapeutics, Inc.

Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. Its current pipeline centers on TARA-002, an investigational cell therapy being studied for non-muscle invasive bladder cancer and lymphatic malformations, and intravenous choline chloride, a phospholipid substrate replacement therapy for patients receiving parenteral nutrition. The company’s programs address areas with significant unmet medical need across oncology, rare disease, gastrointestinal, and metabolic care. Protara Therapeutics operates as a research-driven developer of specialty treatments, with its portfolio aimed at advancing targeted options for patient populations that have limited approved alternatives. Headquartered in New York, New York, the company focuses on clinical development and translational science to support its therapeutic candidates.

CEO Mr. Jesse Shefferman · 46 employees · United States · https://www.protaratx.com